Vaxart is a clinical-stage biotechnology company on a mission to make the world a better and safer place by developing transformative vaccines against common viral infections. They are at the forefront of the Oral Vaccination Movement, aiming to revolutionize the way vaccines are administered. Unlike traditional intramuscular injections, Vaxart's oral vaccine pills target pathogens in the mucosal areas, including the mouth, nose, and gut.

This unique approach triggers strong IgA and T-cell responses, effectively repelling and overwhelming viral invaders. Vaxart has already made significant progress, with Phase II trials underway for its oral vaccine for Covid and Norovirus, making it the only company in the world to reach this stage with a COVID-19 vaccine pill. But their pipeline doesn't stop there.

They are also developing oral vaccines to protect against seasonal influenza, respiratory syncytial virus (RSV), and even a therapeutic vaccine for human papillomavirus (HPV). By providing stronger, broader, and more durable protection in the form of a small pill, Vaxart's vaccines have the potential to be quicker and less expensive to distribute. Join the movement and subscribe to their newsletter to stay updated on their groundbreaking work in oral vaccination